Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2025)
Adaptive Biotechnologies' Total Current Liabilities history spans 8 years, with the latest figure at $89.9 million for Q4 2025.
- For Q4 2025, Total Current Liabilities fell 8.3% year-over-year to $89.9 million; the TTM value through Dec 2025 reached $89.9 million, down 8.3%, while the annual FY2025 figure was $89.9 million, 8.3% down from the prior year.
- Total Current Liabilities for Q4 2025 was $89.9 million at Adaptive Biotechnologies, up from $83.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $122.4 million in Q3 2021 and bottomed at $83.0 million in Q1 2024.
- The 5-year median for Total Current Liabilities is $94.3 million (2023), against an average of $98.8 million.
- The largest annual shift saw Total Current Liabilities surged 36.97% in 2021 before it fell 21.7% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $113.8 million in 2021, then decreased by 3.53% to $109.8 million in 2022, then decreased by 19.83% to $88.0 million in 2023, then grew by 11.4% to $98.1 million in 2024, then dropped by 8.3% to $89.9 million in 2025.
- Per Business Quant, the three most recent readings for ADPT's Total Current Liabilities are $89.9 million (Q4 2025), $83.4 million (Q3 2025), and $92.1 million (Q2 2025).